Catalent unveils ulta-sensitive melamine test for drugs
US contract services firm Catalent has launched a new test service capable of detecting trace amounts of the toxic chemical melamine in pharmaceuticals.
Abraxis dedicates nanobiologics site
Abraxis Health has dedicated its manufacturing facility in Phoenix, Arizona, US which is the result of a $70m (€47m) investment to give the company the nanotech and biologics capacity needed for Abraxane production.
Lonza buys into immunogenicity
Lonza has bolstered its protein design capabilities by acquiring Algonomics, a CRO with technologies which predict immunogenicity to improve development of protein therapeutics and vaccines.
New Jersey R&D sites vital, says Merck CEO
US R&D facilities in Rahway and Kenilworth, New Jersey will remain operational as they are vital to the to the newly formed Merck Schering-Plough group, according to CEO Richard Clark.
Shire extends Medidata trial management contract
Medidata Solutions has won a multi-year extension to its benchmarking and analysis contract with drugmaker Shire.
PharmaForm rolls out contract spray-drying service
US CMO PharmaForm has added spray-drying to its contract offering to capture a share of the ever-present market for drug bioavailability enhancement.
PharmaNet and Phase Forward sign EDC deal
PharmaNet will offer Phase Forward’s InForm EDC and trial management platform to customers under a new deal announced today.
Genzyme targets BBB
Genzyme is evaluating to-BBB’s G-Technology as part of a research collaboration aimed at developing treatments capable of crossing the blood-brain barrier (BBB).
AFMPS OK for NextPharma's sterile product development centre
NextPharma’s sterile product development centre (SPDC) is set to become operational after clearance by Belgian regulators.
Charles River cuts guidance as sales fall
The availability of preclinical capacity and uncertainty created by mergers and healthcare reform have led to pharma exerting pricing pressure on Charles River, decreasing its sales by 13.1 per cent, and it expects the situation to worsen in Q4.
West laying off 100 staff
West Pharmaceutical Services is laying off 100 staff as part of restructuring efforts after its third quarter results fell short of expectations, despite operating profit increasing by 45 per cent.
GSK and Pfizer launch ViiV Healthcare
GSK and Pfizer have launched their HIV focused JV, ViiV Healthcare with the promise that it will undertake “relentless pursuit” of new drugs.
Penn completes phase one of Tredegar plant expansion
Welsh contract services firm Penn Pharmaceuticals has reorganised its transport and delivery infrastructure in the first phase of a £12m (€13.3m) expansion at its facility in Tredegar.
DNA tests required for Trovan claimants after data lost
Pfizer and Nigerian authorities want Trovan compensation claimants to provide DNA samples to confirm their identity, according to former Nigerian Supreme court justice Abubakar Wali.
Novartis invests in China
Novartis is investing $250m (€170m) to construct a facility in China focused on research, development and manufacture of APIs and has earmarked a further $1bn to expand its R&D activities in the country.